Stelios Papadopoulos sold $1.6M of Exelixis (EXEL)

Executed May 15 2025, disclosed May 16 2025, 1 day later.

Value, as filed

$1.6M

36,508 sh across 2 lots

Executed

May 15 2025

the trade date, as filed

Disclosed

May 16 2025

1 day after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

–

purchases only

Returns are measured on stock purchases only.

The filer

SP Stelios Papadopoulos Director profile →

Stelios Papadopoulos (Director) filed 1 Form 4 report in the trailing twelve months (0 purchases, 1 sale), most often in Exelixis, Inc. (EXEL). The largest single filing was $4.4M of EXEL (100,000 sh × $43.55, as filed), executed Nov 12 2025.

The name

EXEL Exelixis, Inc. EXEL · Healthcare · 53 filings in 24 months ticker →

Healthcare · Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat c…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→

Other filings by Stelios Papadopoulos in EXEL

EXELSALE Exelixis, Inc. $4.4M
100,000 sh × $43.55
Exec Nov 12 2025
Filed Nov 13 2025 · 5:30 PM ET